Domestic market share for the key products has grown significantly over same quarter of the previous year. Due to falling crude prices, raw material and consequently the finished goods selling prices have shown a downward trend. This has led to raw material inventory loss, , adversely affecting the bottom-line, but it was partially mitigated by the increased market share to the extent of 17.21.% across its products.

Consolidated Profit after tax for the quarter ended Jun’16 is 19.94crores, up by 14.64% due to strong operational performance and reduction in overall interest cost. Consolidated EBITDA for the quarter ended Jun’16 is 48.14 crores, up by g.g4%. Company was able to keep its working capital cycle to optimum and further reduced the Debt/Equity ratio.

Expanded capacities from the last year’s expansion program have contributed to increased sales, which is evident in the number of units sold. Company recently replied to USFDA’s request for information and is further upgrading its quailty systems, with the help of USFDA consultants.

For more information please visit: www.aartidrugs.co.in

Share :